A Randomized Phase 2 Trial of 177Lu Radiolabeled Anti-PSMA Monoclonal Antibody J591in Patients with High-Risk Castrate, Biochemically Relapsed Prostate Cancer
Abstract
Clinical trial has received WCMC IRB and CTSC approval with enrollment of initial 5 subjects at WCMC. An additional 18 subjects enrolled (15 treated) at participating sub-sites. Reports submitted to WCMC DSMB with recommendation to proceed with enrollment.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2012
- Accession Number
- ADA566933
Entities
People
- Scott T Tagawa
Organizations
- Cornell University